By clicking this button, you agree to our Terms of Service and Privacy Policy. Recce Ltd has been granted a trading halt by the ASX pending the receipt of information from the United States Food and Drug Administration (FDA) following Recceâs recent data submission. The Motley Fool Australia has no position in any of the stocks mentioned. Please refer to our Financial Services Guide (FSG) for more information. How would you best describe yourself? All Instrument Types. BRIEF-Recce Pharmaceuticals Ltd Seeks Trading Halt . In this FREE STOCK REPORT, Scott Phillips just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. How would you best describe yourself? The Motley Fool Australia operates under AFSL 400691. Recce Pharmaceuticals (ASX:RCE), ... a 17.5 per cent discount to the prevailing price ahead of a trading halt on October 7. Company shares have been in a trading halt today so it's not yet sure how shareholders will react to the news. Listen to Our Podcast Search website for: Popular ⦠They have since dropped back a touch but are still up 10.5% to $1.63 at the time of writing. Itâs been a big month for the company, being placed in a trading halt at the start of the month. The Recce Pharmaceuticals Ltd share price has returned from its trading halt on Tuesday and is shooting higher. The rest of the trading day saw price remaining in the range of 3.30-3.33p. Each company boasts strong growth prospects over the next 3 to 5 years, and most importantly each pays a generous (and fully franked) dividend! The Recce Pharmaceuticals Ltd share price has returned from its trading halt on Tuesday and is shooting higher.. The pharmaceutical companyâs shares crashed as much as 15% lower to $1.38 this morning. A$0.97 0.0 0.5% Last Trade - 01/04/21.
jQuery('html, body').animate({ Recce Completes Capital Raising of $27.95m (delivered on Trading halt due date) Positive & Concentration-Dependent Efficacy Against COVID-19 (delivered one day early) RCE Selected by CSIRO/PDI for SARS-CoV-2 Antiviral Program (delivered on Trading halt due date) Positive Data on RECCE 327 Against Influenza A (delivered on Trading halt due date) Despite its share price weakness today, the Recce share price is up over 360% since the start of the year. These stocks are trading at dirt-cheap prices and Scott thinks they are great buys right now. The approval is not to sell anything or to allow general use anywhere, it is purely the approval they have been waiting for to start this skin application trial. How Much Money Do I Need To Start Investing? A positive result would most certainly lift the SP considerably and I don't think RCE would have trouble raising the capital needed for phase 2 studies. Quotes. Recce Pharmaceuticals Ltd (RCE) is a drug discovery and development business commercialising a new class of synthetic antibiotics with broad spectrum activity designed to address the global health challenge of antibiotic resistant superbugs. Everything You Need to Know About Tech Investing. Hear our experts take on shares, the market & how to invest. All Instrument Types; Indices; Equities; ETFs; Funds; Commodities; Currencies; Crypto; Bonds ; Certificates; No results matched your search. April 16 (Reuters) - Recce Pharmaceuticals Ltd: * REQUESTS A TRADING HALT PENDING ANNOUNCEMENT RELATING TO ANTIVIRAL TEST RESULTS Source text for ⦠Audeara (AUA) has finished its first full trading on the ASX, after carrying out a successful $7 million initial public offering (IPO). The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. When investing expert Scott Phillips has a stock tip, it can pay to listen. This comprises the RECCE 327, RECCE 435 and RECCE 529 compounds which are addressing the urgent global health problems of antibiotic resistant superbugs and emerging viral pathogens. Investment news, stock ideas, and more, straight to your inbox. Antibiotic maker Recce Pharmaceuticals (RCE) has had two of its key products chosen for an important government antiviral screening program to ⦠On September 10, Recce announced it had enlisted CMAX Clinical Research to undertake a phase one clinical study of its RECCE 327 antibiotic. © 2009 – 2021 The Motley Fool Australia Pty Ltd. All rights reserved. Thank you! }); event.preventDefault();
Financial Services Guide | The pharmaceutical company’s shares crashed as much as 15% lower to $1.38 this morning. The company's lead candidate is RECCE 327 to treat blood infections and sepsis derived from E. coli and S. aureus bacteria, including their superbug forms. The Motley Fool Australia does not guarantee the performance of, or returns on any investment. It also develops RECCE 529, a synthetic anti-infective for viral infections; and RECCE ⦠About Recce Pharmaceuticals Ltd Recce Pharmaceuticals Ltd (ASX: RCE) is pioneering the development and commercialisation of New Classes of Synthetic Anti-Infectives designed to ⦠As trading continued in the morning, price bounced off of the 3.3p support twice. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of antibiotics. Subscription Terms of Service, ACN: 146 988 052 | Australian Financial Services Licence (AFSL): 400691, The Motley Fool Australia, PO Box 4635, Ashmore, Qld 4214, jQuery(document).on('click', 'a[href^="#"]', function (event) { For more information please see our Financial Services Guide. We will use your email address only to keep you informed about updates to our website and about other products and services we think might interest you. Following a trading halt that began on Monday afternoon, yesterday Recce announced it has entered into an antiviral SARS-CoV-2 screening program agreement. Halt times displayed are Eastern Time (ET). Speculative. Our Top 5 Stocks for Investors 50 or Older – NOW AVAILABLE! Wednesday saw an initial jump to 3.48 and then 3.51p. Investors have been selling Recce’s shares after it completed a placement of shares to institutional, professional and sophisticated investors. This represents a sizeable 20% discount to its last close price. scrollTop: jQuery(jQuery.attr(this, 'href')).offset().top The company raised a total of approximately $28 million before costs at an issue price of $1.30 per share. e.preventDefault(); The Recce Pharmaceuticals Ltd (ASX: RCE) share price has returned from its trading halt on Tuesday and is shooting higher. Read detailed company information and latest announcements from Recce Pharmaceuticals Ltd including news headlines & gain/loss. Thank you! All Instrument Types; Indices; Equities; ETFs; Funds; Commodities; Currencies; Crypto; Bonds; Certificates ; No results matched your search. Get Started Investing This ensures it is fully funded to complete its Phase I human clinical trial, SARSCoV-2 (COVID-19) pre-clinical program, Helicobacter pylori preclinical program, and the anticipated Phase I/II topical study at a leading Australian teaching hospital. });*/, Why the Recce Pharmaceuticals (ASX:RCE) share price crashed 15% lower today, 10 Stocks To Buy (including 2 Every Investor Should Own), Setting Yourself Up for Success Before You Start. Recce Pharmaceuticals (RCE) broke out of a trading halt and soared today after revealing positive anti-COVID results from its RECCE-327 (R327) product The drug is being tested against SARS-CoV-2, which is the virus that causes COVID-19, as part of a CSIRO and Doherty Institute screening program It seems fairly clear the trading halt is because they have recieved a response to the request for HREC approval to begin phase 1 trial of topical skin use. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*. All Instrument Types. How would you best describe yourself? Finally closing at 3.3p (-4.35% from Monday's closing price). .fool-ecap.fool-ecap-id-19.fool-ecap-type-vanilla {background: #fff7c4;} aside section .fool-ecap-id-19.fool-ecap-type-vanilla h3 {font-size: 1.6em;} p.ecap-disclaimer {font-size: 0.6em!important;}div.fool-ecap.fool-ecap-id-19 form {position: relative;text-align: center;margin: .2em 1em;}.fool-ecap.fool-ecap-id-19 p.ecap-disclaimer {margin-left: 0px;} .fool-ecap.fool-ecap-id-19 p.above-email{ margin-bottom: 0px;text-align:center;} div.fool-ecap.fool-ecap-id-19 p {color: #464646;}.fool-ecap-type-vanilla.fool-ecap-id-19 h3 {color: #404040;display: block !important;}.fool-ecap-type-vanilla.fool-ecap-id-19 .ecap-disclaimer{color: #484848 !important;}.fool-ecap-id-19.fool-ecap-type-vanilla h3.title{display:none !important;} .fool-ecap.fool-ecap-id-19.fool-ecap-type-vanilla{ margin-bottom: 10px;}.fool-ecap-type-vanilla.fool-ecap-id-19 input[type="submit"] { margin: .5rem 0 .5rem !important;}.fool-ecap.fool-ecap-id-19 img {display: inline;}. They have since recovered the majority of this decline but are still down over 3% to $1.58 at the time of writing. Recce Pharmaceuticals' : Anti-Infective Drug Effective Against ESKAPE Pathogens in Study; Shares Jump 4% /*document.querySelectorAll('a[href^="#"]').forEach(anchor => { On the basis of these findings, Recce has been issued a qualified recommendation to proceed to stage two of the programme; Recce Pharmaceuticals shares closed the day in the grey to trade at $1.13; Recce Pharmaceuticals (RCE) has reported further findings from its fee-for-service collaboration between the CSIRO and the Doherty Institute. Breaking News. Authorised by Scott Phillips. Be the first with the news that moves the market, ASX Today: Rebound to continue despite ore dive, Infinity Lithium Corporation (ASX:INF) shares crash amid Spanish permit cancellation, The “gas-fired” investment opportunity in the Australian energy sector, Imugene (ASX:IMU) expands patent portfolio with City of Hope, Province Resources (ASX:PRL) enters trading halt ahead of fresh capital raise, AnteoTech (ASX:ADO) signs COVID-19 test manufacturing contract, Great Northern Minerals’ (ASX:GNM) shares jump on high-grade results from Camel Creek, Recce Pharmaceuticals (RCE) has paused its shares pending an upcoming capital raising, The company's shares will remain paused until the earlier of September 23 or when the announcement is made, On September 10, Recce announced it had enlisted CMAX Clinical Research to undertake a phase 1 clinical study of its RECCE 327 antibiotic, REECE 327 is a synthetic antibiotic used to treat blood infections and sepsis derived from E. coli and Staphylococcus aureus bacteria, This trial will assess 48 healthy adult patients to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of REECE 327, Shares in Recce last traded for $1.64 on September 18. This trial will assess 48 healthy adult patients to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamic profile of REECE 327. Just trying to clarify as some seem to think it might apply to or mean something else. This study tested the R327 and R529 drugs against the COVID-19 virus and results showed that both showed increasing efficacy as the doses increased. Recce’s Chief Executive Officer, James Graham, commented: “We greatly appreciate the support shown by both our existing investors and new institutional investors. BRIEF-Recce Pharmaceuticals Requests Trading Halt Pending Announcement . Their financial support comes at a transformative time for Recce as we prepare to advance human clinical trials. Likes. Recce Pharmaceuticals Ltd (RCE) Announcements. Sector Healthcare RiskRating. They have since dropped back a touch but are still up 10.5% to $1.63 at the time of writing. }); Wall Street analysts have given Recce Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. You can unsubscribe at anytime. Happy days! Happy days! Current Trading Halts .document.querySelector(this.getAttribute('href')).scrollIntoView({ Please remember that investments can go up and down. Pause Threshold Price. Recce Pharmaceuticals (RCE) has completed its capital raise and successfully raised $27.95 million. Breaking News. Recce launched the capital raising in order to fund the advancement of its synthetic anti-infective pipeline. Learn about investing with our Investing Education hub. The company notes that there will be additional financial support from the Australian Government’s 43.5% R&D rebate on R&D applicable activities. The company's shares will remain in a trading halt until the earlier of September 23, or when the announcement is made. Mind you, Mr Graham sees joy in penury because the tight funding position has instilled management with a disciplined approach to spending. MarketBeat just released five new trading ideas, but Recce Pharmaceuticals wasn't one of them. In afternoon trade the biotechnology companyâs shares rocketed as much as 27% higher to a record high of $1.87 at one stage. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. Thank you! Toro Energy (TOE) has placed its shares in a trading halt while it gears up for an approaching capital raise. The Recce Pharmaceuticals Ltd (ASX: RCE) share price has come under pressure on Wednesday after returning from its trading halt. So if you’re looking to get your finances on track and you’re in or near retirement – we’ve got you covered! They have since recovered the majority of this decline but are still down over 3% to $1.58 at the time of writing. Quotes. anchor.addEventListener('click', function (e) { Once trading resumed Recce Pharmaceuticals came out with a flurry of announcements. Equus Mining (EQE) has placed its shares in a trading halt while it plans an upcoming capital raising. They have since recovered the majority of this decline but are still down over 3% to $1.58 at the time of writing. The company's synthetic anti-infective drug R327 is being tested against SARS-CoV-2, the virus that causes COVID-19, in further stage 1B studies conducted by the parties. Once trading resumed Recce Pharmaceuticals came out ⦠Individual Investor Institutional Investor Financial Advisor Active Trader. Shares in Recce last traded for $1.64 on September 18. July 6 (Reuters) - Recce Pharmaceuticals Ltd: * SEEKS TRADING HALT PENDING ANNOUNCEMENT ON MATERIAL RESEARCH AGREEMENT Source text ⦠The antibiotic maker entered a trading halt on September 21 but did not disclose how much it would be raising. Its patented lead candidate known as RECCE 327 has been developed for the treatment of blood infections and sepsis derived from E. coli and S. aureus bacteria - ⦠Recce Pharmaceuticals Ltd, formerly Recce Limited, is an Australia-based research-based pharmaceutical company. Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. Our latest articles and strategies for the post-work life you want. The pharmaceutical companyâs shares crashed as much as 15% lower to $1.38 this morning. Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Recce Pharmaceuticals. }, 500); Scott just revealed what he believes are the five best ASX stocks for investors to buy right now. Recce Pharmaceuticals Ltd, a biotechnology company, engages in the research, development, and commercialization of synthetic antibiotics in Australia, the United States, and the United Kingdom. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. RCE - Recce Pharmaceuticals Share News. The Complete Guide to Planning For Your Retirement, Setting up an SMSF: 10 Things You Need to Know Before Starting, 3 easy steps to building your ASX share portfolio for an early retirement, 4 tips on how to pick winning stocks for your retirement share portfolio, This is the best asset to own to start saving for your early retirement, Commonwealth Bank of Australia (ASX: CBA), Flight Centre Travel Group Ltd (ASX: FLT), Vanguard Australian Shares Index (ASX: VAS). It’s been a big month for the company, being placed in a trading halt at the start of the month. Shares in Recce Pharmaceuticals are currently trading at A$1.11 and the price has moved by 0.127k% over the past 365 days. This Service provides only general, and not personalised financial advice, and has not taken your personal circumstances into account. Recce Pharmaceuticals Ltd has raised about $1.8 million from sophisticated and institutional investors via a share placement at 14 cents per ⦠Home / Share Market News / Share Fallers / Why the Recce Pharmaceuticals (ASX:RCE) share price crashed 15% lower today, James Mickleboro | September 23, 2020 12:29pm | More on: RCE. Recce last entered a trading halt in early September pending the release of anti-viral testing results. Sign Up for Take Stock Trading Halt RSS Feed. Privacy Policy | The Company is principally engaged in ⦠All Instrument Types; Indices; Equities; ETFs; Funds; Commodities; Currencies; Crypto ; Bonds; Certificates; No results matched your search. Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange. Recce Pharmaceuticals (RCE) has paused its shares pending an upcoming capital raising. The Recce Pharmaceuticals Ltd share price has come under pressure on Wednesday after returning from its trading halt.. The Recce Pharmaceuticals Ltd (ASX: RCE) share price has come under pressure on Wednesday after returning from its trading halt. In afternoon trade the biotechnology companyâs shares rocketed as much as 27% higher to a record high of $1.87 at one stage. Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. Past performance is not necessarily indicative of future returns. In terms of relative price strength - which takes into account the overall market trend - the Recce Pharmaceuticals price has moved by 71.67% over the past year. Based on these results Recce has been advised it should advance research of both drugs. Find the investing style that's right for you. On September 10, Recce announced it had enlisted CMAX Clinical Research to undertake a phase one clinical study of its RECCE 327 antibiotic. Individual Investor Institutional Investor Financial Advisor Active Trader. All Instrument Types. Mind you, Mr Graham sees joy in penury because the tight funding position has instilled management with a disciplined approach to spending. RCE Share Price and Trading History RELATED STOCKHEAD STORIES We welcome all new investors and look forward to updating the market as our pivotal trials progress in the coming months.”. For a limited time, The Motley Fool Australia is giving away an urgent new investment report outlining our 5 favourite stocks for investors over 50. The coming months will soon reveal whether investors were right to back this one. The Motley Fool has a disclosure policy. There certainly is a lot of optimism around these compounds. ASX 200 | A B C D E F G H I J L M N O P Q R S T U V W X. If the phase 1 result is bad it would be game over and no more money needed. Individual Investor Institutional Investor Financial Advisor Active Trader. View the full Corporate Spotlight Recce Pharmaceuticals (RCE) has reported further findings from its fee-for-service collaboration between the CSIRO and the Doherty Institute. Join Our Premium Community The Australian-based company will begin trading on the exchange today under the code R9Q with no affiliated capital raising activities. }); Juno Minerals (JNO), a new company made up of Jupiter Mines’ demerged iron ore assets, has made its debut on the ASX. Recce Pharmaceuticals is up a healthy 3.06 per cent trading at $1.01; Reccce Pharamceuticals (RCE) has become a dual-lister after assuming its position on a major German exchange. Recce Pharmaceuticals (ASX: ... a 17.5 per cent discount to the prevailing price ahead of a trading halt on October 7. REECE 327 is a synthetic antibiotic used to treat blood infections and sepsis derived from E. coli and Staphylococcus aureus bacteria. Terms of Service | behavior: 'smooth' RCE Price at posting: $1.64 Sentiment: Hold Disclosure: Held. This article contains general investment advice only (under AFSL 400691). In afternoon trade the biotechnology company’s shares … Join our flagship membership service, Share Advisor. You can do it. Recce Pharmaceuticals Ltd (ASX:RCE) is an Australian based globally-focussed, biotechnology company engaged in the development and commercialisation of a new class of synthetic anti-infectives. Recce Pharmaceuticals (RCE) broke out of a trading halt and soared today after revealing positive anti-COVID results from its RECCE-327 (R327) product; The drug is being tested against SARS-CoV-2, which is the virus that causes COVID-19, as part of a CSIRO and Doherty Institute screening program Recce Pharmaceuticals (ASX: RCE) emerged from a trading halt to announced that two of its drug candidates would be used in an upcoming antiviral SARS-Cov-2 screening program. The company's shares will remain in a trading halt until the earlier of September 23, or when the announcement is made. Win at Retirement ASX:RCE - Investor presentation, announcements, cashflow waterfall chart, news, capital raise history, & sector peers. A day later the company announced it had received positive results from early studies of two compounds being tested against the SARS-CoV-2 virus. BRIEF-Recce Pharmaceuticals Seeks Trading Halt . Recce Pharmaceuticals (RCE) has paused its shares pending an upcoming capital raising. Quotes. Breaking News. Recce Pharmaceuticals Ltd (RCE) is a drug discovery and development business commercialising a new class of synthetic antibiotics with broad spectrum activity designed to address the global health challenge of antibiotic resistant superbugs.